ArticleCancer2020
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Financial Hardship, End-of-Life Health Care Use, and Costs in Patients With Cancer.JAMA network open · 2026Article
- Improving outcomes of patients with advanced prostate cancer through a better understanding of clinical factors contributing to financial toxicity: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Impact of In-Office Dispensing Adoption by Urology Practices on Oral Specialty Drug Use in Advanced Prostate Cancer.Cancer medicine · 2026Article
- Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the United States Medicare Fee-for-Service Population.Urology practice · 2025Article
- Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist.Cancer medicine · 2025Article
- Treatment Landscape for Older Men With Metastatic Hormone-Sensitive Prostate Cancer in the United States.Cancer medicine · 2025Article
- Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.Future oncology (London, England) · 2025Article
- The 340B Drug Pricing Program and Management of Advanced Prostate Cancer.Cancer medicine · 2025Article
- Article
- Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer.Urology practice · 2024Article
- Prior Authorization and Association With Delayed or Discontinued Prescription Fills.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Adherence to Hormonal Therapies in Prostate Cancer.Urology practice · 2023Review
- New technology in prostate cancer and financial toxicity.Urologic oncology · 2023Review
- Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Medicare Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity.Urology practice · 2023Article
- In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer.JNCI cancer spectrum · 2023Article
- Association between low-income subsidies and inequities in orally administered antimyeloma therapy use.The American journal of managed care · 2023Article
- Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.JCO oncology practice · 2023Article
- Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer.The Journal of urology · 2023Review
- Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review.Therapeutic advances in medical oncology · 2023Article
- The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.Journal of the National Cancer Institute · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAbiraterone and enzalutamide are high-cost oral therapies that increasingly are used to treat patients with advanced prostate cancer; these agents carry the potential for significant financial consequences to patients. In the current study, the authors investigated coping and material measures of the financial hardship of these therapies among patients with Medicare Part D coverage.
methodsThe authors performed a retrospective cohort study on a 20% sample of Medicare Part D enrollees who underwent treatment with abiraterone or enzalutamide between July 2013 and June 2015. The authors described the variability in adherence rates and out-of-pocket payments among hospital referral regions in the first 6 months of therapy and determined whether adherence and out-of-pocket payments were associated with patient factors and the socioeconomic characteristics of where a patient was treated.
resultsThere were 4153 patients who filled abiraterone or enzalutamide prescriptions through Medicare Part D in 228 hospital referral regions. The mean adherence rate was 75%. The median monthly out-of-pocket payment for abiraterone and enzalutamide was $706 (range, $0-$3505). After multilevel, multivariable adjustment for patient and regional factors, adherence was found to be lower in patients who were older (69% for patients aged ≥85 years vs 76% for patients aged <70 years; P < .01) and in those with low-income subsidies (69% in those with a subsidy vs 76% in those without a subsidy; P < .01). Both Hispanic ethnicity and living in a hospital referral region with a higher percentage of Hispanic beneficiaries were found to be independently associated with higher out-of-pocket payments for abiraterone and enzalutamide.
conclusionsThere were substantial variations in the adherence rate and out-of-pocket payments among Medicare Part D beneficiaries who were prescribed abiraterone and enzalutamide. Sociodemographic patient and regional factors were found to be associated with both adherence and out-of-pocket payments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.